Statements (66)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:administered_by |
oral tablet
intravenous injection |
| gptkbp:approves |
gptkb:FDA
gptkb:EMA |
| gptkbp:atccode |
J04 AB02
|
| gptkbp:available_on |
generic drug
|
| gptkbp:brand |
gptkb:Rifadin
gptkb:Rimactane |
| gptkbp:can_be_combined_with |
gptkb:ethambutol
gptkb:isoniazid gptkb:pyrazinamide |
| gptkbp:casnumber |
13292-46-1
|
| gptkbp:category |
gptkb:C
|
| gptkbp:chemical_formula |
C43 H58 N4 O12
|
| gptkbp:class |
gptkb:rifamycins
|
| gptkbp:composed_by |
semi-synthetic
|
| gptkbp:contraindication |
liver disease
pregnancy severe renal impairment hypersensitivity to rifampin |
| gptkbp:developed_by |
gptkb:Amycolatopsis_rifamycinica
Danish pharmaceutical company |
| gptkbp:discovered_by |
gptkb:1957
|
| gptkbp:dissolved |
soluble in organic solvents
slightly soluble in water |
| gptkbp:duration |
1 to 2 years for leprosy
6 to 12 months for tuberculosis |
| gptkbp:excretion |
urine
bile |
| https://www.w3.org/2000/01/rdf-schema#label |
rifampin
|
| gptkbp:initiated_by |
mycobacterial growth
|
| gptkbp:interacts_with |
gptkb:warfarin
oral contraceptives antiretroviral drugs |
| gptkbp:is_monitored_by |
liver function tests
complete blood count |
| gptkbp:lifespan |
2 to 5 hours
|
| gptkbp:mechanism_of_action |
inhibits bacterial RNA synthesis
|
| gptkbp:side_effect |
nausea
vomiting diarrhea rash thrombocytopenia acute kidney injury hepatotoxicity flu-like symptoms hypersensitivity reactions flu-like syndrome orange discoloration of bodily fluids red-orange urine |
| gptkbp:storage |
room temperature
|
| gptkbp:treatment |
active tuberculosis
latent tuberculosis infection |
| gptkbp:used_for |
treating leprosy
preventing meningococcal disease treating tuberculosis |
| gptkbp:bfsParent |
gptkb:Trypanosoma
gptkb:Sovaldi gptkb:Biktarvy gptkb:ledipasvir gptkb:pibrentasvir gptkb:velpatasvir gptkb:Epclusa gptkb:Harvoni |
| gptkbp:bfsLayer |
5
|